Mr. Shadday has more than 20 years of global commercial expertise in strategic and operational marketing and sales functions with leadership roles in US, Europe, Latin America and Asia Pacific.
Before joining Breath Therapeutics, Mr. Shadday served as global marketing lead at Vertex for its next-generation modulator programs for the treatment of cystic fibrosis. Prior, he was Vice President and Global Business Leader at Lundbeck and led the global product launch of the novel antidepressant Brintellix/Trintellix. Previously, Mr. Shadday was Director of International and Global Commercial Strategy at Gilead Sciences, responsible for the hepatitis, anti-fungal and respiratory therapeutic franchises. Earlier, he held several commercial positions at Novartis in Europe, the US and South America.
Mr. Shadday earned a B.A. in Economics from Yale University and is a graduate of the Ecole Supérieure de Commerce de Paris.